Optimized Pooled Testing Cuts Costs for Infectious Disease Screening
Researchers developed an optimized pooled testing framework, enabling faster, cost-effective, and accurate infectious disease screening.
Read MorePosted by Andy Lundin | Dec 11, 2024 | Diagnostic Technologies |
Researchers developed an optimized pooled testing framework, enabling faster, cost-effective, and accurate infectious disease screening.
Read MorePosted by Andy Lundin | Dec 4, 2024 | Sequencing Systems |
Delve Bio’s Delve Detect is a metagenomic sequencing test capable of quickly identifying over 68,000 pathogens from CSF.
Read MorePosted by Andy Lundin | Sep 4, 2024 | Company News |
QIAGEN and AstraZeneca will develop a genotyping assay for companion diagnostics, advancing testing for therapies targeting chronic diseases.
Read MorePosted by Andy Lundin | May 20, 2024 | Infectious Diseases |
The Karius Test, a diagnostic tool for lung infections in immunocompromised patients, received Breakthrough Device Designation from the FDA.
Read MorePosted by Andy Lundin | Apr 17, 2024 | Infectious Diseases |
Delve Bio announced data on the use of mNGS for the definitive diagnosis of infectious causes of meningitis and/or encephalitis.
Read More